Literature DB >> 18959602

The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals.

M Montagnana1, C Fava, P M Nilsson, G Engström, B Hedblad, G Lippi, P Minuz, G Berglund, O Melander.   

Abstract

BACKGROUND: To determine if the common Pro12Ala polymorphism (rs1801282) of the peroxisome proliferator-activated receptor (PPARG) gene is associated with the metabolic syndrome (MetS) or with its individual components in middle-aged Swedish individuals.
METHODS: MetS was defined according to the National Cholesterol Education Program/Adult Panel III (NCEP/ATP III), the International Diabetes Federation (IDF) and the European Group for the Study of Insulin Resistance (EGIR) criteria in a population-based sample of nearly 5000 subjects participating in the Malmö Diet and Cancer-cardiovascular arm.
RESULTS: Of the subjects included in the analysis, 21.8, 29.4 and 20.4% had MetS according to the NCEP/ATP III, IDF and EGIR (only in subjects without diabetes) definitions, respectively. The Pro12Ala was not associated with MetS or with its individual components. These results were similar when patients with diabetes were excluded. Hypertensive and obese ala-carriers had lower fasting glucose and hypertensive ala-carriers also had lower level triglycerides (P < 0.05).
CONCLUSIONS: Our data do not support a major role for the Pro12Ala variant of the PPARG gene in MetS and its individual components. The modest difference in triglyceride and glucose levels, restricted to hypertensive and obese subjects in our cohort, suggests that the polymorphism has a minor effect on glucose and lipid metabolism, particularly in individuals at risk for gluco-metabolic disturbances.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18959602     DOI: 10.1111/j.1464-5491.2008.02510.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Development of ARMS-PCR assay for genotyping of Pro12Ala SNP of PPARG gene: a cost effective way for case-control studies of type 2 diabetes in developing countries.

Authors:  Mehboob Islam; Fazli Rabbi Awan; Shahid Mahmood Baig
Journal:  Mol Biol Rep       Date:  2014-07-26       Impact factor: 2.316

Review 2.  Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome.

Authors:  Chen Dong; Hui Zhou; Chong Shen; Lu-Gang Yu; Yi Ding; Yong-Hong Zhang; Zhi-Rong Guo
Journal:  World J Diabetes       Date:  2015-05-15

3.  G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis.

Authors:  Shujin Li; Chuan He; Haiyan Nie; Qianyin Pang; Ruixia Wang; Zhifu Zeng; Yongyan Song
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

4.  Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population.

Authors:  Abdul Haseeb; Mohammad Iliyas; Subhabrata Chakrabarti; Arif A Farooqui; Sudhir R Naik; Sudip Ghosh; Madhuri Suragani; Nasreen Z Ehtesham
Journal:  J Biosci       Date:  2009-09       Impact factor: 1.826

5.  ASSOCIATION OF THE HUMAN PPARγ2 PRO12ALA POLYMORPHISM WITH OBESITY IN A POPULATION FROM TURKEY.

Authors:  M A Sözen; M U Özcan; M Çıldır; I H Doğru; A G Aygök; K Ü Balkan
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

6.  Association of the variants in the PPARG gene and serum lipid levels: a meta-analysis of 74 studies.

Authors:  Qing Li; Rong Chen; Lizhan Bie; Dandan Zhao; Chunkai Huang; Jiang Hong
Journal:  J Cell Mol Med       Date:  2014-09-30       Impact factor: 5.310

7.  [Nutrigenetics: potentials and applications in cardiovascular diseases and associated risk factors].

Authors:  Maria Daniela Defagó; Aldo Renato Eynard
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2022-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.